XML 209 R127.htm IDEA: XBRL DOCUMENT
v3.22.4

Collaborative and Other Relationships - Mosunetuzumab (Details) - Mosunetuzumab - USD ($) $ in Millions | 1 Months Ended | 12 Months Ended
--- | --- | ---
Jan. 31, 2022 | Dec. 31, 2022 | Dec. 31, 2021
Collaborative arrangements and non-collaborative arrangement transactions |  |  |
Option exercise fee | $ 30.0 |  |
Development of product candidate expense |  |  | $ 20.0
Percentage of future development costs |  | 30.00% | 30.00%
Research and development expense asset acquired |  | $ 28.4 |
Sales and marketing expense |  | $ 13.0 |

X
- Definition Percentage Of Future Development Costs + References No definition available. + Details
Name: | biib_PercentageOfFutureDevelopmentCosts
Namespace Prefix: | biib_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research and Development Expense, Development Of Product Candidate + References No definition available. + Details
Name: | biib_ResearchAndDevelopmentExpenseDevelopmentOfProductCandidate
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Research And Development Expense, Option Exercise Fee + References No definition available. + Details
Name: | biib_ResearchAndDevelopmentExpenseOptionExerciseFee
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 730 -Section 25 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate total amount of expenses directly related to the marketing or selling of products or services. + References No definition available. + Details
Name: | us-gaap_SellingAndMarketingExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=biib_MosunetuzumabMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |